These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37667106)

  • 1. High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.
    Sims EK; Geyer SM; Long SA; Herold KC
    Diabetologia; 2023 Dec; 66(12):2283-2291. PubMed ID: 37667106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.
    Mathieu C; Wiedeman A; Cerosaletti K; Long SA; Serti E; Cooney L; Vermeiren J; Caluwaerts S; Van Huynegem K; Steidler L; Blomme S; Rottiers P; Nepom GT; Herold KC;
    Diabetologia; 2024 Jan; 67(1):27-41. PubMed ID: 37782353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
    Herold KC; Gitelman SE; Willi SM; Gottlieb PA; Waldron-Lynch F; Devine L; Sherr J; Rosenthal SM; Adi S; Jalaludin MY; Michels AW; Dziura J; Bluestone JA
    Diabetologia; 2013 Feb; 56(2):391-400. PubMed ID: 23086558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
    Sims EK; Bundy BN; Stier K; Serti E; Lim N; Long SA; Geyer SM; Moran A; Greenbaum CJ; Evans-Molina C; Herold KC;
    Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
    Ramos EL; Dayan CM; Chatenoud L; Sumnik Z; Simmons KM; Szypowska A; Gitelman SE; Knecht LA; Niemoeller E; Tian W; Herold KC;
    N Engl J Med; 2023 Dec; 389(23):2151-2161. PubMed ID: 37861217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
    Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
    Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
    Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
    Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.
    Sims EK; Cuthbertson D; Jacobsen L; Ismail HM; Nathan BM; Herold KC; Redondo MJ; Sosenko J
    J Clin Endocrinol Metab; 2024 Jul; 109(8):2116-2123. PubMed ID: 38267821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes.
    Sims EK; Chaudhry Z; Watkins R; Syed F; Blum J; Ouyang F; Perkins SM; Mirmira RG; Sosenko J; DiMeglio LA; Evans-Molina C
    Diabetes Care; 2016 Sep; 39(9):1519-26. PubMed ID: 27385327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proinsulin to C-Peptide Ratio in the First Year After Diagnosis of Type 1 Diabetes.
    Freese J; Al-Rawi R; Choat H; Martin A; Lunsford A; Tse H; Mick G; McCormick K
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4318-e4326. PubMed ID: 34228132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.
    Herold KC; Gitelman SE; Gottlieb PA; Knecht LA; Raymond R; Ramos EL
    Diabetes Care; 2023 Oct; 46(10):1848-1856. PubMed ID: 37607392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis.
    Kamrul-Hasan ABM; Mondal S; Nagendra L; Yadav A; Aalpona FTZ; Dutta D
    Endocr Pract; 2024 May; 30(5):431-440. PubMed ID: 38519028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
    Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
    N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
    Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
    Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.
    Van Dalem A; Demeester S; Balti EV; Keymeulen B; Gillard P; Lapauw B; De Block C; Abrams P; Weber E; Vermeulen I; De Pauw P; Pipeleers D; Weets I; Gorus FK;
    PLoS One; 2016; 11(12):e0166702. PubMed ID: 27907006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS).
    Loopstra-Masters RC; Haffner SM; Lorenzo C; Wagenknecht LE; Hanley AJ
    Diabetologia; 2011 Dec; 54(12):3047-54. PubMed ID: 21959959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes.
    Desouter AK; Keymeulen B; Demeester S; Van de Velde U; De Pauw P; Van Dalem A; Lapauw B; De Block C; Gillard P; Pipeleers DG; Gorus FK
    Diabetes Res Clin Pract; 2023 Nov; 205():110974. PubMed ID: 37884063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes.
    Truyen I; De Pauw P; Jørgensen PN; Van Schravendijk C; Ubani O; Decochez K; Vandemeulebroucke E; Weets I; Mao R; Pipeleers DG; Gorus FK;
    Diabetologia; 2005 Nov; 48(11):2322-9. PubMed ID: 16211374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proinsulin-to-C-Peptide Ratio as a Marker of β-Cell Function in African American and European American Adults.
    Couch CA; Piccinini F; Fowler LA; Garvey WT; Gower BA
    Diabetes Care; 2023 Dec; 46(12):2129-2136. PubMed ID: 36787895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.
    Sims EK; Cuthbertson D; Herold KC; Sosenko JM
    Diabetes; 2021 Dec; 70(12):2922-2931. PubMed ID: 34551936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.